C Diff Drug Development

C Diff Drug Development

974 bookmarks
Custom sorting
Chicoric Acid Alleviates Colitis via Targeting the Gut Microbiota Accompanied by Maintaining Intestinal Barrier Integrity and Inhibiting Inflammatory Responses - PubMed
Chicoric Acid Alleviates Colitis via Targeting the Gut Microbiota Accompanied by Maintaining Intestinal Barrier Integrity and Inhibiting Inflammatory Responses - PubMed
Polyphenols have shown great potential to prevent ulcerative colitis. As a natural plant polyphenol, chicoric acid (CA) has antioxidant and anti-inflammatory properties. This study explored the intervention effects and potential mechanism of CA on dextran sodium sulfate (DSS)-induced colitis mice. T …
·pubmed.ncbi.nlm.nih.gov·
Chicoric Acid Alleviates Colitis via Targeting the Gut Microbiota Accompanied by Maintaining Intestinal Barrier Integrity and Inhibiting Inflammatory Responses - PubMed
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection - PubMed
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection - PubMed
SER-109 (VOWST™; fecal microbiota spores, live-brpk) is a live biotherapeutic product indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in patients 18 years of age and older following standard of care (SOC) antibacterial treatment for recurrent CDI. It is a p …
·pubmed.ncbi.nlm.nih.gov·
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection - PubMed
Clostridium Difficile Infections Market Outlook and Forecast: Analyzing Major Market Trends, Population Segmentation, and Therapeutics Developments in the APAC Region | Acurx, Crestone, MGB Biopharma, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed
Clostridium Difficile Infections Market Outlook and Forecast: Analyzing Major Market Trends, Population Segmentation, and Therapeutics Developments in the APAC Region | Acurx, Crestone, MGB Biopharma, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed
DelveInsight s Clostridium Difficile Infections Patient Pool Analysis Market Size and Market Forecast APAC 2034 report provides comprehensive insights into the historical and projected patient burden treatable patient population and notable market trends across the APAC region India China South ...
·news.google.com·
Clostridium Difficile Infections Market Outlook and Forecast: Analyzing Major Market Trends, Population Segmentation, and Therapeutics Developments in the APAC Region | Acurx, Crestone, MGB Biopharma, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed
Anionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeutic - PubMed
Anionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeutic - PubMed
Thuricin CD is a two-peptide antimicrobial produced by Bacillus thuringiensis. Unlike previous antibiotics, it has shown narrow spectrum activity against Clostridioides difficile, a bacterium capable of causing infectious disease in the colon. However, peptide antibiotics have stability, solubility, …
·pubmed.ncbi.nlm.nih.gov·
Anionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeutic - PubMed
Core-genome-mediated promising alternative drug and multi-epitope vaccine targets prioritization against infectious Clostridium difficile - PubMed
Core-genome-mediated promising alternative drug and multi-epitope vaccine targets prioritization against infectious Clostridium difficile - PubMed
Prevention of Clostridium difficile infection is challenging worldwide owing to its high morbidity and mortality rates. C. difficile is currently being classified as an urgent threat by the CDC. Devising a new therapeutic strategy become indispensable against C. difficile infection due to its high r …
·pubmed.ncbi.nlm.nih.gov·
Core-genome-mediated promising alternative drug and multi-epitope vaccine targets prioritization against infectious Clostridium difficile - PubMed
Pro-Inflammatory Cytokines Enhanced In Vitro Cytotoxic Activity of Clostridioides difficile Toxin B in Enteric Glial Cells: The Achilles Heel of Clostridioides difficile Infection? - PubMed
Pro-Inflammatory Cytokines Enhanced In Vitro Cytotoxic Activity of Clostridioides difficile Toxin B in Enteric Glial Cells: The Achilles Heel of Clostridioides difficile Infection? - PubMed
Bacterial infections are characterized by an inflammatory response, which is essential for infection containment but is also responsible for negative effects on the host. The pathogen itself may have evolved molecular mechanisms to antagonize the antimicrobial effects of an inflammatory response and …
·pubmed.ncbi.nlm.nih.gov·
Pro-Inflammatory Cytokines Enhanced In Vitro Cytotoxic Activity of Clostridioides difficile Toxin B in Enteric Glial Cells: The Achilles Heel of Clostridioides difficile Infection? - PubMed
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy - PubMed
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy - PubMed
Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stems from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical …
·pubmed.ncbi.nlm.nih.gov·
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy - PubMed
Gut Microbiota-Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy - PubMed
Gut Microbiota-Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy - PubMed
Clostridioides difficile (C. difficile) infection (CDI) is the most common hospital-acquired infection. With the combination of a high rate of antibiotic resistance and recurrence, it has proven to be a debilitating public health threat. Current treatments for CDI include antibiotics a …
·pubmed.ncbi.nlm.nih.gov·
Gut Microbiota-Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy - PubMed
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response - PubMed
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response - PubMed
Although ridinilazole did not meet superiority in SCR, ridinilazole greatly reduced rCDI and preserved microbiome diversity and SBAs compared with vancomycin. These findings suggest that treatment of CDI with ridinilazole results in an earlier recovery of gut microbiome health. Clinical Trials Regis …
·pubmed.ncbi.nlm.nih.gov·
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response - PubMed
Synthesis and antimicrobial activity of thiophene-based heterocycles derived from thiophene-2-carbohydrazide - PubMed
Synthesis and antimicrobial activity of thiophene-based heterocycles derived from thiophene-2-carbohydrazide - PubMed
Aim: Thiophene-based heterocycles were synthesized and evaluated for their antimicrobial activity against methicillin-resistant Staphylococcus aureus, Escherichia coli, Clostridium difficile and Candida albicans strains. Methods: Antimicrobial activity was determined usin …
·pubmed.ncbi.nlm.nih.gov·
Synthesis and antimicrobial activity of thiophene-based heterocycles derived from thiophene-2-carbohydrazide - PubMed
Antimicrobial Guanidinylate Polycarbonates Show Oral In Vivo Efficacy Against Clostridioides Difficile - PubMed
Antimicrobial Guanidinylate Polycarbonates Show Oral In Vivo Efficacy Against Clostridioides Difficile - PubMed
The emerging antibiotic resistance has been named by the World Health Organization (WHO) as one of the top 10 threats to public health. Notably, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VREF) are designated as serious threats, whereas Clostri …
·pubmed.ncbi.nlm.nih.gov·
Antimicrobial Guanidinylate Polycarbonates Show Oral In Vivo Efficacy Against Clostridioides Difficile - PubMed
Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant - PubMed
Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant - PubMed
Clostridioides difficile infection (CDI) is a serious healthcare-associated disease, causing symptoms such as diarrhea and pseudomembranous colitis. The major virulence factors responsible for the disease symptoms are two secreted cytotoxic proteins, TcdA and TcdB. A parenteral vaccine based on form …
·pubmed.ncbi.nlm.nih.gov·
Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant - PubMed
Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection - PubMed
Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection - PubMed
Clostridioides difficile is the leading cause of antibiotic-associated infectious diarrhea. The development of C.difficile infection is tied to perturbations of the bacterial community in the gastrointestinal tract, called the gastrointestinal microbiota. Repairing the gastrointestinal microbiota by …
·pubmed.ncbi.nlm.nih.gov·
Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection - PubMed
A rationally designed antimicrobial peptide from structural and functional insights of Clostridioides difficile translation initiation factor 1 - PubMed
A rationally designed antimicrobial peptide from structural and functional insights of Clostridioides difficile translation initiation factor 1 - PubMed
A significant increase of hospital-acquired bacterial infections during the COVID-19 pandemic has become an urgent medical problem. Clostridioides difficile is an urgent antibiotic-resistant bacterial pathogen and a leading causative agent of nosocomial infections. The increasing recurrence o …
·pubmed.ncbi.nlm.nih.gov·
A rationally designed antimicrobial peptide from structural and functional insights of Clostridioides difficile translation initiation factor 1 - PubMed
Lumen Bioscience granted FDA fast track for C. difficile treatment
Lumen Bioscience granted FDA fast track for C. difficile treatment
Lumen Bioscience has announced that the US Food and Drug Administration (FDA) has granted fast track designation for LMN-201, its biologic drug to treat and prevent C. difficile infection (CDI).
·news.google.com·
Lumen Bioscience granted FDA fast track for C. difficile treatment
Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from Clostridioides difficile-Induced Mortality - PubMed
Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from Clostridioides difficile-Induced Mortality - PubMed
Clostridioides difficile causes life-threatening diarrhea and is one of the leading causes of nosocomial infections. During infection, C. difficile releases two gut-damaging toxins, TcdA and TcdB, which are the primary determinants of disease pathogenesis and are important therapeutic …
·pubmed.ncbi.nlm.nih.gov·
Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from Clostridioides difficile-Induced Mortality - PubMed
Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant - PubMed
Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant - PubMed
Clostridioides difficile infection (CDI) is a serious healthcare-associated disease, causing symptoms such as diarrhea and pseudomembranous colitis. The major virulence factors responsible for the disease symptoms are two secreted cytotoxic proteins, TcdA and TcdB. A parenteral vaccine based on form …
·pubmed.ncbi.nlm.nih.gov·
Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant - PubMed
Differentiating Between Live Biotherapeutic Products and Conventional FMTs
Differentiating Between Live Biotherapeutic Products and Conventional FMTs
Without regulations for donation practices for conventional fecal microbiota transplants (FMT), clinicians need to consider which therapeutic agents for recurrent C difficile treatment to utilize.
·news.google.com·
Differentiating Between Live Biotherapeutic Products and Conventional FMTs
A rationally designed antimicrobial peptide from structural and functional insights of Clostridioides difficile translation initiation factor 1 - PubMed
A rationally designed antimicrobial peptide from structural and functional insights of Clostridioides difficile translation initiation factor 1 - PubMed
A significant increase of hospital-acquired bacterial infections during the COVID-19 pandemic has become an urgent medical problem. Clostridioides difficile is an urgent antibiotic-resistant bacterial pathogen and a leading causative agent of nosocomial infections. The increasing recurrence o …
·pubmed.ncbi.nlm.nih.gov·
A rationally designed antimicrobial peptide from structural and functional insights of Clostridioides difficile translation initiation factor 1 - PubMed
Antimicrobial Guanidinylate Polycarbonates Show Oral in Vivo Efficacy Against Clostridioides Difficile - PubMed
Antimicrobial Guanidinylate Polycarbonates Show Oral in Vivo Efficacy Against Clostridioides Difficile - PubMed
The emerging antibiotic resistance has been named by the World Health Organization (WHO) as one of the top 10 threats to public health. Notably, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VREF) are designated as serious threats, whereas Clostri …
·pubmed.ncbi.nlm.nih.gov·
Antimicrobial Guanidinylate Polycarbonates Show Oral in Vivo Efficacy Against Clostridioides Difficile - PubMed
Pfizer's New C. difficile Awareness Initiative Explained | Pfizer
Pfizer's New C. difficile Awareness Initiative Explained | Pfizer
Pfizer recently convened experts representing a cross-section of healthcare professionals and patient organizations for a panel titled, “Clostridioides difficile: A public health threat in plain sight.” They first met during a panel discussion that coincided with Infectious Disease (ID) Week in late-2019 and served as a launchpad for the C.
·pfizer.com·
Pfizer's New C. difficile Awareness Initiative Explained | Pfizer
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
A toxoid-based Clostridioides difficile vaccine is currently in development. Here, we report lot-to-lot consistency, immunogenicity, safety, and toler…
·news.google.com·
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age